Although the functionality of these mutations has not been fully clarified, mutations in SRGAP3 and KMT2D have been detected and considered relevant in a variety of sarcomas, including angiosarcoma, endometrial stromal sarcoma and alveolar rhabdomyosarcoma [49,50,51,52,53]. This evidence concerns the gene SRGAP3 and sarcoma.